Trial Profile
Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Oct 2022
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Churg-Strauss syndrome; Granulomatosis with polyangiitis; Microscopic polyangiitis
- Focus Therapeutic Use
- Acronyms STATVAS
- 13 Apr 2021 Status changed from active, no longer recruiting to completed.
- 23 Oct 2019 Route and form assumed form RDI.
- 18 Oct 2019 Planned End Date changed from 1 Apr 2020 to 1 Nov 2019.